ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank50
3Y CAGR-16.7%
5Y CAGR+10.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-16.7%/yr
vs +4.5%/yr prior
5Y CAGR
+10.8%/yr
Recent deceleration
Acceleration
-21.2pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.7x
Solid growth
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 27.28% |
| 2024 | 54.39% |
| 2023 | 30.35% |
| 2022 | 47.16% |
| 2021 | 29.71% |
| 2020 | 16.37% |
| 2019 | 26.73% |
| 2018 | 39.53% |
| 2017 | 13.48% |
| 2016 | 31.54% |